NCT03111589View on ClinicalTrials.gov

Monocytic Expression of Heme Oxidase-1 (HO-1) in Sickle Cell Patients and Correlation With the Humoral Immune Response to Vaccine and With Allo-immunization.

NACompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions
Sickle Cell Disease
Interventions
BIOLOGICAL

Inactivated influenza A (H1N1) virus vaccine

All groups of patients and the control group will receive the new annually recommended inactivated influenza A (H1N1) virus vaccine.

DIAGNOSTIC_TEST

Blood sampling

Testing of the different humoral immune responses to vaccines or to erythrocyte alloantigens.

Trial Locations (2)

1020

CHU Brugmann, Brussels

HUDERF, Brussels

All Listed Sponsors
lead

Francis Corazza

OTHER

NCT03111589 - Monocytic Expression of Heme Oxidase-1 (HO-1) in Sickle Cell Patients and Correlation With the Humoral Immune Response to Vaccine and With Allo-immunization. | Biotech Hunter | Biotech Hunter